Form 4: Oncocyte Corp Director Lou Silverman Acquires 30,000 Stock Options

Director Lou Silverman acquired 30,000 stock options in Oncocyte Corp on July 1, 2024.

Summary

• On July 1, 2024, Lou Silverman, a director of Oncocyte Corp, acquired 30,000 stock options.
• The exercise price of these options is $2.95.
• The options vest one year from the grant date, contingent upon Silverman's continued service as a director.
• The options expire on July 1, 2034.
• Following the transaction, Silverman directly owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider activity can be a positive signal, this is a relatively small transaction and doesn't necessarily indicate a strong bullish or bearish outlook.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

Industry Context

This transaction is a routine disclosure of insider activity, which is common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates